Patents Assigned to Universitatsklinikum Freiburg
  • Publication number: 20140050741
    Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 20, 2014
    Applicants: UNIVERSITEIT LEIDEN, UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
  • Patent number: 8632777
    Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: January 21, 2014
    Assignee: Universitätsklinikum Freiburg
    Inventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
  • Publication number: 20130309264
    Abstract: The present invention relates to antigens, more particularly protein antigens of enterococcal pathogens which are useful as vaccine components for therapy and/or prophylaxis.
    Type: Application
    Filed: November 3, 2011
    Publication date: November 21, 2013
    Applicant: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Hübner, Elisabeth Grohmann, Andrea Kropec-Hübner
  • Publication number: 20130109629
    Abstract: The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Applicant: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Gernot Zissel, Joachim Müller-Quernheim, Antje Prasse
  • Publication number: 20130059861
    Abstract: The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these cells. The level of ROS can be increased by increasing the level of nitric oxide through inhibition of the enzymes nitric oxide dioxygenase or arginase. According to the present invention inhibitors of the nitric oxide dioxygenase or arginase can be used for the manufacture of a medicament for the treatment of cancer. The present invention further provides a method for identifying compounds which can be used for the treatment of cancer, wherein the method allows to specifically identify compounds which induce apoptosis through the ROS signaling pathway. The present invention also provides a kit for identifying compounds which induce tumor apoptosis by inactivating a catalase on the tumor cell surface.
    Type: Application
    Filed: September 27, 2012
    Publication date: March 7, 2013
    Applicant: Universitätsklinikum Freiburg
    Inventor: Universitätsklinikum Freiburg
  • Publication number: 20120329854
    Abstract: The present invention provides in vitro methods for detecting, grading or prognosticating cancer, in particular prostate cancer. The invention further provides isolated polynucleotides suitable for reducing or inhibiting the expression of protein kinase C beta I and/or II and/or alpha (and consequently the levels of histone H3 phosphorylated at threonine 6, histone H3 monomethylated at lysine 4, histone H3 dimethylated at lysine 4, histone H3 trimethylated at lysine 4) and further relates to pharmaceutical compositions comprising said polynucleotides for the treatment or prevention of cancer, in particular prostate cancer.
    Type: Application
    Filed: August 3, 2010
    Publication date: December 27, 2012
    Applicant: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Eric Metzger, Roland Schüle
  • Patent number: 8293494
    Abstract: The invention relates to a multiple-specificity demethylase complex comprising a Jumonji C (JMJC) domain-containing enzyme, a process of its preparation and its use.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: October 23, 2012
    Assignee: Universitatsklinikum Freiburg
    Inventors: Roland Schüle, Eric Metzger, Melanie Wissmann
  • Patent number: 8288088
    Abstract: The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these cells. The level of ROS can be increased by increasing the level of nitric oxide through inhibition of the enzymes nitric oxide dioxygenase or arginase. According to the present invention inhibitors of the nitric oxide dioxygenase or arginase can be used for the manufacture of a medicament for the treatment of cancer. The present invention further provides a method for identifying compounds which can be used for the treatment of cancer, wherein the method allows to specifically identify compounds which induce apoptosis through the ROS signaling pathway. The present invention also provides a kit for identifying compounds which induce tumor apoptosis by inactivating a catalase on the tumor cell surface.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: October 16, 2012
    Assignee: Universitatsklinikum Freiburg
    Inventor: Georg Bauer
  • Patent number: 8282932
    Abstract: Disclosed are split-core carrier substance which, as separate polypeptide, have the core N domain and the core C domain of the core protein of a hepatitis B virus and at least one foreign molecule against which an immune response is to be induced. According to the invention, the foreign molecule, especially the heterologous foreign amino acid sequence, is fused to the C terminus or the core N domain or to the N terminus of the core C domain and the core protein can form capsid-like particles. The invention also relates to the associated production method.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: October 9, 2012
    Assignee: Universitatsklinikum Freiburg
    Inventors: Michael Nassal, Claudia Skamel, Andreas Walker
  • Patent number: 8039640
    Abstract: The invention relates to new morphine compounds of the formula: where R1 represents a C1-6 alkyl radical and the radicals R2 and R3 are independently selected from the group consisting of hydrogen atoms, methyl groups and acetyl groups.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: October 18, 2011
    Assignee: Universitätsklinikum Freiburg
    Inventor: Rainer Trittler
  • Publication number: 20100081703
    Abstract: The invention relates to a multiple-specificity demethylase complex comprising a Jumonji C (JMJC) domain-containing enzyme, a process of its preparation and its use.
    Type: Application
    Filed: January 7, 2008
    Publication date: April 1, 2010
    Applicant: UNIVERSITATSKLINIKUM FREIBURG
    Inventors: Roland Schüle, Eric Metzger, Melanie Wissmann
  • Patent number: 7687083
    Abstract: Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6% by weight of an extract of Usnea barbata, containing 96% of usnic acid, and 40% by weight of an extract of Hypericum perforatum, containing 39% of hyperforin, together. The pharmaceutical composition leads to a potentiation of the anti-inflammatory and antimicrobial effects of the extracts and to stabilization of the hyperforin. The combination is suitable for the external and internal treatment of various skin diseases, in particular skin inflammations and skin ageing, and for the treatment of skin infections with pityrosporon yeast fungi, acne and rosacea.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: March 30, 2010
    Assignee: Universitatsklinikum Freiburg
    Inventors: Christoph Mathis Schempp, Andrea Jocher, Kathrin Engel, Constance Huyke
  • Publication number: 20100040646
    Abstract: Disclosed are split-core carrier substances which, as separate polypeptides, have the core N domain and the core C domain of the core protein of a hepatitis B virus and at least one foreign molecule against which an immune response is to be induced. According to the invention, the foreign molecule, especially the heterologous foreign amino acid sequence, is fused to the C terminus of the core N domain or to the N terminus of the core C domain and the core protein can form capsid-like particles. The invention also relates to the associated production method.
    Type: Application
    Filed: July 12, 2007
    Publication date: February 18, 2010
    Applicant: Universitatsklinikum Freiburg
    Inventors: Michael Nassal, Claudia Skamel, Andreas Walker
  • Publication number: 20100034749
    Abstract: The present invention relates to cationic colloidal preparations and their use for the diagnosis and/or treatment of ocular diseases.
    Type: Application
    Filed: July 9, 2007
    Publication date: February 11, 2010
    Applicants: MediGene AG, Universitatsklinikum Freiburg
    Inventors: Brita Schulze, Uwe Michaella, Hansjürgen Agostini, Jing Hua, Eric Guenzi, Gottfried Martin, Lutz Hansen
  • Publication number: 20090264398
    Abstract: The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these cells. The level of ROS can be increased by increasing the level of nitric oxide through inhibition of the enzymes nitric oxide dioxygenase or arginase. According to the present invention inhibitors of the nitric oxide dioxygenase or arginase can be used for the manufacture of a medicament for the treatment of cancer. The present invention further provides a method for identifying compounds which can be used for the treatment of cancer, wherein the method allows to specifically identify compounds which induce apoptosis through the ROS signaling pathway. The present invention also provides a kit for identifying compounds which induce tumor apoptosis by inactivating a catalase on the tumor cell surface.
    Type: Application
    Filed: August 7, 2007
    Publication date: October 22, 2009
    Applicant: Universitatsklinikum Freiburg
    Inventor: Georg Bauer
  • Patent number: 7572218
    Abstract: An implantable muscle closing prosthesis system, particularly for opening and closing the rectum, characterized in that it has a compression unit, which comprises a compression cuff (1) and a reservoir cuff (2) molded as hollow bodies, and may integrate a bidirectional micropump (4) of arbitrary construction via a support ring (3), the cuffs primarily being subjected to a material compression during the inflation and deflation and communicating with one another via the micropump (4), which may be activated using a separate control unit, or is also manually operable from the outside.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: August 11, 2009
    Assignee: Universitatsklinikum Freiburg
    Inventor: Hans-Jurgen Schrag
  • Publication number: 20090012110
    Abstract: The invention relates to new morphine compounds of the formula: where R1 represents a C1-6 alkyl radical and the radicals R2 and R3 are independently selected from the group consisting of hydrogen atoms, methyl groups and acetyl groups.
    Type: Application
    Filed: February 15, 2007
    Publication date: January 8, 2009
    Applicant: Universitatsklinikum Freiburg
    Inventor: Rainer Trittler
  • Publication number: 20080233145
    Abstract: Pharmaceutical compositions of Usnea barbata and the use thereof for the treatment of skin diseases are disclosed. A preferred composition is the combination with an extract of Hypericum perforatum. The extracts are obtained by supercritical high-pressure extraction with spring carbon-dioxide. A preferred form of preparation is the homogenization of 6% by weight of an extract of Usnea barbata, containing 96% of usnic acid, and 40% by weight of an extract of Hypericum perforatum, containing 39% of hyperforin, together. The pharmaceutical composition leads to a potentiation of the anti-inflammatory and anti-microbial effects of the extracts and to stabilization of the hyperforin. The combination is suitable for the external and internal treatment of various skin diseases, in particular skin inflammations and skin ageing, and for the treatment of skin infections with pityrosporon yeast fungi, acne and rosacea.
    Type: Application
    Filed: April 7, 2005
    Publication date: September 25, 2008
    Applicant: UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Christoph Mathis Schempp, Andrea Jocher, Kathrin Engel, Constance Huyke
  • Patent number: 7411395
    Abstract: A magnetic resonance tomography apparatus, includes a gradient system that can generate at least one spatially varying and optionally time-varying magnetic field for at least one-dimensional local encoding of measuring signals in an area of a test sample to be imaged. The gradient system contains at least one subsystem which can generate a non-bijective spatially varying magnetic (NBSEM) field for local encoding, such that the function of the field strength of such an NBSEM within the area to be imaged has at least one local extreme value (maximum or minimum), such that the area to be imaged is divided along the hyper surface formed by the entirety of all local extreme values of the at least one NBSEM. The apparatus can produce images of the same quality with smaller magnetic field differences and permits easy realization.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: August 12, 2008
    Assignee: Universitätsklinikum Freiburg
    Inventor: Jürgen Hennig
  • Patent number: 7372266
    Abstract: A method according to the technique of a steady state free precession (SSFP) gradient echo method, in particular, of nuclear magnetic resonance (NMR) tomography, wherein a regular sequence of radio frequency pulses with flip angle ? is applied at temporally constant intervals TR, wherein the phase of these pulses is increased in subsequent steps by a constant phase increment, is characterized in that a predetermined phase encoding scheme is performed in such a manner that each individual phase encoding step is identically repeated N times under the following conditions: N is an even number and N?2; successive measured NMR signals are averaged, which minimizes the artefacts produced due to incrementation of the phase encoding gradients.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 13, 2008
    Assignee: Universitätsklinikum Freiburg
    Inventors: Michael Markl, Jochen Leupold